The prevailing clinical picture of high blood pressure as a simple plumbing problem — too much pressure on passive vessel walls — is being fundamentally redrawn. Emerging evidence positions the outermost arterial layer, the adventitia, as an active immunological command center that can both accelerate and precede dangerous blood pressure elevation, with implications for how cardiovascular risk is assessed and treated.
This review in Atherosclerosis synthesizes the mechanistic chain linking adventitial biology to systemic vascular damage. Hypertension drives effector memory T cells to accumulate in the adventitia and surrounding perivascular adipose tissue, a process orchestrated by the chemokine RANTES/CCL5. Once resident, these immune cells release IL-17A and IFN-γ, cytokines that trigger endothelial dysfunction, superoxide overproduction, and collagen deposition through p38 MAP kinase signaling. Critically, chronic oxidative stress generates isolevuglandin (IsoLG)-protein adducts — reactive lipid-oxidation products that bind native proteins and create neoantigens. These neoantigens activate dendritic cells and T cells, producing aortic stiffening that measurably predates overt hypertension. Stiffened arteries then lose their Windkessel buffering capacity, amplifying microvascular shear stress and immune signaling in the kidney, brain, and coronary circulation — completing a feed-forward injury loop.
What makes this framework analytically significant is the causal inversion it implies: adventitial immune activation is not downstream fallout from elevated pressure but a co-driver of the hypertensive state itself. This repositions perivascular inflammation alongside traditional hemodynamic metrics as a therapeutic target. Prior work on T-cell depletion and IL-17 blockade in animal models has shown blood pressure attenuation, and IsoLG scavengers are under early investigation. The review's major limitation is its reliance on preclinical and mechanistic data; large human trials directly targeting adventitial pathways remain absent. Nevertheless, the mechanistic coherence and multi-organ scope make this a potentially paradigm-shifting synthesis for cardiovascular medicine, elevating arterial wall immunology to a first-order clinical consideration.